貓疫苗市場機會、成長促進因素、產業趨勢分析與預測 2025 - 2034 年

2024年全球貓疫苗市場價值為11億美元，預計2025年至2034年複合年成長率為9.2%。疫苗接種對於保護貓免受傳染病至關重要，包括貓白血病、呼吸道疾病和狂犬病，這些疾病在家貓和流浪貓中都很常見。隨著越來越多的人了解寵物預防性保健的重要性，對貓疫苗的需求持續上升。

此外，人們越來越關注可以從動物傳播給人類的人畜共患疾病，這增加了對疫苗接種的重視，特別是預防狂犬病等疾病。這種意識的增強導致疫苗的使用量增加，越來越多的寵物主人投資於貓咪健康的預防措施。此外，寵物保險的擴大使用以及寵物護理產品和服務的激增也促進了市場的成長。

貓疫苗旨在保護伴侶動物，尤其是貓，免受一系列傳染病的侵害。這些疫苗透過刺激免疫系統發揮作用，從而防止疾病傳播並促進室內和室外貓的整體健康。

市場依疫苗類型分為改良/減毒活疫苗、去活化疫苗和其他疫苗類型。改良/減毒活疫苗所佔佔有率最大，到2024年將佔市場的50.5%。這些疫苗可以針對貓白血病、全白血球減少症和呼吸道疾病等疾病提供持久的保護，特別是在動物收容所等高風險環境中。

貓疫苗市場也依疾病類型分為貓白血病、全白血球減少症、呼吸道疾病、狂犬病等類別。貓呼吸道疾病，包括貓皰疹病毒和杯狀病毒，佔最大部分，因為它們具有高度傳染性，並且對貓具有重大健康風險，特別是在多貓環境中。

疫苗經由注射或鼻內途徑施用。注射疫苗因其經過驗證的有效性、易於使用和快速的免疫反應而在市場上佔據主導地位。這些疫苗通常以組合配方形式提供，單劑量即可提供針對多種疾病的保護，使它們對寵物主人來說既方便又有吸引力。

聯合疫苗領域引領市場，一次性提供多種疾病的保護。這些疫苗減少了去看獸醫和注射的次數，使貓更負擔得起並減輕壓力。

市場也根據免疫期限進行細分，疫苗提供 1 年、3 年或其他期限。一年期免疫疫苗最受歡迎，以其長期的安全記錄和功效而聞名，鞏固了其在市場上的主導地位。

在北美，由於擁有大量寵物的人口和強大的獸醫基礎設施，美國佔有重要的市場佔有率，這增加了獲得疫苗和獸醫護理的機會，進一步促進了市場成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 增加寵物擁有量和寵物健康支出
    • 預防性寵物保健意識不斷增強
    • 疫苗技術的進步
  • 產業陷阱與挑戰
    • 疫苗研發成本高
    • 嚴格的監管要求
• 成長潛力分析
• 監管環境
• 管道分析
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按疫苗類型，2021 - 2034 年

• 主要趨勢
• 修改/減弱的現場
• 去活化
• 其他疫苗類型

第 6 章：市場估計與預測：按疾病類型，2021 - 2034 年

• 主要趨勢
• 貓呼吸道疾病
• 貓白血病
• 貓泛白血球減少症（貓瘟）
• 貓咪狂犬病
• 其他疾病類型

第 7 章：市場估計與預測：按管理途徑，2021 - 2034 年

• 主要趨勢
• 注射劑
• 鼻內

第 8 章：市場估計與預測：按組成部分，2021 - 2034 年

• 主要趨勢
• 聯合疫苗
• 單一疫苗

第 9 章：市場估計與預測：按豁免期限分類，2021 - 2034 年

• 主要趨勢
• 1年
• 3年
• 其他免疫期限

第 10 章：市場估計與預測：按地區分類，2021 - 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：公司簡介

• Bioveta
• Boehringer Ingelheim
• Durvet
• Elanco
• Indian Immunologicals
• INTAS Animal Health
• Merck
• Spectra
• Virbac
• Zoetis

The Global Cat Vaccines Market, valued at USD 1.1 billion in 2024, is anticipated to grow at a CAGR of 9.2% from 2025 to 2034. The primary drivers of this market expansion include the rising awareness of animal health and an increasing number of pet owners worldwide. Vaccination is critical in safeguarding cats from infectious diseases, including feline leukemia, respiratory conditions, and rabies, which are common among both domestic and stray cats. As more people understand the importance of preventative healthcare for their pets, the demand for cat vaccines continues to rise.

Additionally, the growing concern over zoonotic diseases, which can be transmitted from animals to humans, has increased the emphasis on vaccinations, particularly to prevent diseases like rabies. This growing awareness has led to an increased uptake of vaccines, with more pet owners investing in preventive measures for their cats' health. Furthermore, the expanding use of pet insurance and the surge in pet care products and services also contribute to the market growth.

Cat vaccines are designed to protect companion animals, especially cats, from a range of infectious diseases. These vaccines work by stimulating the immune system, thereby preventing the spread of illnesses and promoting the overall health of both indoor and outdoor cats.

The market is segmented based on vaccine type into modified/attenuated live, inactivated, and other vaccine types. The modified/attenuated live vaccines hold the largest share, accounting for 50.5% of the market in 2024. Their effectiveness, ability to trigger strong immune responses, and cost-effectiveness make them highly favored by veterinarians and pet owners. These vaccines provide long-lasting protection against diseases like feline leukemia, panleukopenia, and respiratory illnesses, particularly in high-risk environments such as animal shelters.

The cat vaccines market is also divided by disease type into categories like feline leukemia, panleukopenia, respiratory diseases, rabies, and others. Feline respiratory diseases, including Feline Herpesvirus and Calicivirus, represent the largest segment, due to their high contagiousness and significant health risks to cats, particularly in multi-cat environments.

The vaccines are administered either through injectables or intranasal routes. Injectable vaccines dominate the market because of their proven effectiveness, ease of use, and quick immune response. These vaccines, often available in combination formulations, provide protection against multiple diseases in a single dose, making them convenient and appealing to pet owners.

The combined vaccines segment leads the market, offering protection against several diseases in one shot. These vaccines reduce the number of vet visits and injections, making them more affordable and less stressful for cats.

The market is also segmented by the duration of immunity, with vaccines offering 1-year, 3-year, or other durations. The 1-year immunity vaccines are the most popular, known for their long-standing safety record and efficacy, which solidifies their dominant position in the market.

In North America, the U.S. holds a significant market share, driven by its large pet-owning population and strong veterinary infrastructure, which enhances access to vaccines and veterinary care, further promoting market growth.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing pet ownership and spending on pet health
    • 3.2.1.2 Growing awareness of preventive pet healthcare
    • 3.2.1.3 Advancements in vaccine technology
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High development cost of vaccines
    • 3.2.2.2 Stringent regulatory requirement
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Modified/attenuated live
• 5.3 Inactivated
• 5.4 Other vaccine types

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Feline respiratory diseases
• 6.3 Feline leukemia
• 6.4 Feline panleukopenia (feline distemper)
• 6.5 Feline rabies
• 6.6 Other disease types

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Injectables
• 7.3 Intranasal

Chapter 8 Market Estimates and Forecast, By Component, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Combined vaccine
• 8.3 Mono vaccine

Chapter 9 Market Estimates and Forecast, By Duration of Immunity, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 1 year
• 9.3 3 years
• 9.4 Other durations of immunity

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Italy
  • 10.3.5 Spain
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Bioveta
• 11.2 Boehringer Ingelheim
• 11.3 Durvet
• 11.4 Elanco
• 11.5 Indian Immunologicals
• 11.6 INTAS Animal Health
• 11.7 Merck
• 11.8 Spectra
• 11.9 Virbac
• 11.10 Zoetis